NO. 46

CIMR Wednesday Lecture Series

Time:

Wednesday, Nov. 6 2024, 4:00 p.m.

Location:

Yifu Lecture Hall, North Basic Research Building 

Host：

Deguang Liang (梁德光)

Chinese Institutes for Medical Research, Beijing

Speaker：

Hongbin Ji (季红斌)

Investigator

Center for Excellence in Molecular Cell Science

Chinese Academy of Sciences

TITLE：

Transdifferentiation of Lung Adenosquamous Carcinoma and Drug Resistance to Targeted Therapy

ABSTRACT:

KRASG12C inhibitors (adagrasib and sotorasib) have shown clinical promise in targeting KRASG12C-mutated lung cancers; however, most patients eventually develop resistance. In lung patients with adenocarcinoma with KRASG12C and STK11/LKB1 co-mutations, we find an enrichment of the squamous cell carcinoma gene signature in pre-treatment biopsies correlates with a poor response to adagrasib. Studies of Lkb1-deficient KRASG12C and KrasG12D lung cancer mouse models and organoids treated with KRAS inhibitors reveal tumors invoke a lineage plasticity program, adeno-to-squamous transition (AST), that enables resistance to KRAS inhibition. Transcriptomic and epigenomic analyses reveal ΔNp63 drives AST and modulates response to KRAS inhibition. We identify an intermediate high-plastic cell state marked by expression of an AST plasticity signature and Krt6a. Notably, expression of the AST plasticity signature and KRT6A at baseline correlates with poor adagrasib responses. These data indicate the role of AST in KRAS inhibitor resistance and provide predictive biomarkers for KRAS-targeted therapies in lung cancer.

SELECTED PAPERS